Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | PDE4A | P27815 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2972012 | 0.93 | CALM1 (0.41) | CALM1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7315399 | 0.91 | CALM1 (0.56) | CALM1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7253321 | 0.91 | PDE4A (0.52) | CALM1KMT2AALDH1A1PDE4AMAPT | |
| SCHEMBL6035149 | 0.88 | MEN1 (0.56) | KMT2AMAPK1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL11823484 | 0.86 | PDE4A (0.42) | CALM1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL12824881 | 0.84 | BIRC5 (0.45) | KMT2AMAPK1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL6895161 | 0.84 | ALDH1A1 (0.50) | KMT2AMAPK1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL4380153 | 0.84 | ALDH1A1 (0.49) | CALM1KMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL6430844 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HPGD | |
| SCHEMBL2704054 | 0.81 | TACR2 (0.47) | CALM1KMT2AMAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777060-B2 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | claimed |
| CN-120908328-A | Method for measuring impurity content in 3, 4-diethoxyphenethylamine by utilizing HPLC | 江苏联环药业股份有限公司 | 2025-11-07 | — | — | CN | disclosed |
| CN-120559138-A | Method for measuring related substances of 3, 4-diethoxyphenylacetic acid by utilizing HPLC | 江苏联环药业股份有限公司 | 2025-08-29 | — | — | CN | disclosed |
| CN-115073372-A | Preparation method of drotaverine hydrochloride degradation impurities | 江苏联环药业股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-111170847-B | Novel method for preparing drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-111170847-B | Novel method for preparing drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-109796351-B | Novel preparation method of drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-109796351-B | Novel preparation method of drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-111170847-A | Novel method for preparing drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-111170847-A | Novel method for preparing drotaverine hydrochloride intermediate | 江苏联环药业股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-2114394-B1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-7777060-B2 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2114394-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008100301-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008100301-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194680-A1 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-4126615-A | RANEY NICKEL CATALYST | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1978-11-21 | — | — | US | disclosed |
| US-3984559-A | Compositions comprising tetramic acid analogs of pulvinic acid and methods of combating arthritis | SMITHKLINE CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
| US-3947580-A | Anti-arthritic compositions comprising N-heterocyclic pulvinic acid amides and methods of producing anti-arthritic activity | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
| US-3931207-A | ANTIARTHRITIC | SMITHKLINE CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194680-A1 | Platinum analogs with bis-nitrile-containing ligands | PCNA, LIG4, TOP2B | CALM1 4783/4885KMT2A 3453/4885MAPK1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.